Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: A phase II evaluation

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2765-2770

  Kirpensteijn, J ^a   Teske, E ^a   Kik, M ^a   Klenner, Th ^b   Rutteman, G R ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ASTA MEDICA AG   (Germany)

Author keywords

Canine; Chemotherapy; Lobaplatin; Osteosarcoma

Indexed keywords

ALKALINE PHOSPHATASE; LOBAPLATIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPENDICULAR OSTEOSARCOMA; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOG; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; INTOXICATION; LEUKOPENIA; MALE; METASTASIS; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR NECROSIS; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOBUTANES; DOG DISEASES; DOGS; FEMALE; FORELIMB; HINDLIMB; MALE; ORGANOPLATINUM COMPOUNDS; OSTEOSARCOMA;

EID: 0036765961     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Withrow SJ, Powers BE Straw RC and Wilkins RM: Comparative aspects of osteosarcoma. Dog versus man. Clin Orthopedics Rel Res 270: 159-68, 1991.
2. MacEwen EG:Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment. Cancer Metastasis Rev 9(2): 125-36, 1990.
3. Hahn KA, Bravo L Adams WH and Frazier DL: Naturally occurring tumors as comparative models for cancer therapy research. In Vivo 8: 133-44, 1994.
4. Whelan JS: Pediatric update: Osteosarcoma. Eur J Cancer 33(10): 1611-9, 1997.
5. Meyers PA and Gorlick R: Osteosarcoma. Pediatr Clin North Am 44(4): 973, 1997.
6. Spodnick GJ, Berg J, Rand W M, Schelling SH, Couto CG, Harvey JH, Henderson RA, MacEwen EG, Mauldin GN and McCaw DL: Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 200: 995-9, 1992.
7. Brodey RS and Abt DA: Results of surgical treatment in 65 dogs with osteosarcoma. J Am Vet Med Assoc 168:1032-5, 1976.
8. Shapiro W, Fossum TW, Kitchell BE, Couto CG and Theilen GH: Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 192: 507-11, 1988.
9. Berg J, Weinstein MJ, Springfield DS and Rand WM: Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 206: 1555-60, 1995.
10. Hahn KA, Richardson RC, Blevins WE, Lenz SD and Knapp DW: Intramedullary cisplatin chemotherapy: Experience in four dogs with osteosarcoma. J Small Anim Pract 37: 187-92, 1996.
11. Kraegel SA, Madewell BR, Simonson E and Gregory CR: Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Amer Veterinary Med Assoc 1998: 1057-9, 1991.
12. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, LaRue SM, Ogilvie GK, Vail DM, Morrison WB, McGee M and Dickinson K: Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 5: 205-10, 1991.
13. Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hale A, Kruth SA, Klein MK, Klausner J, Norris AM, McCaw D, Straw RC and Withrow SJ: Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991-1993). J Vete Intern Med 10(2): 76-81, 1996.
14. Page R, McEntee MC, George SL, Williams PE, Heidner GL, Novotney CA, Riviere JE, Dewhirst MW and Thrall DE: Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med 7: 235-40, 1993.
15. Berg J, Gebhardt MC, and Rand WM: Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 79: 1343-1350, 1997.
16. Cotter SM and Parker LM: High-dose methotrexate and leucovorin rescue in dogs with osteogenic sarcoma. Am J Vet Res 39: 1943-5, 1978.
17. Mauldin GN, Matus RE, Withrow SJ and Patnaik AK: Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 2: 177-80, 1988.
18. Ettinger LJ, Douglass HO, Higby DJ, Mindell ER, Nime F, Ghoorah J and Freeman AI: Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. Cancer 47: 248-54, 1981.
19. Henness AM, Theilen GH, Park RD and Buhles WC: Combination therapy for canine osteosarcoma. J Am Vet Med Assoc 170: 1076-81, 1977.
20. Harstrick A, Bokemeyer C, Scharnofske M, Hapke G, Reile D and Schmoll H-J: Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and-resistant human testicular, ovarian and gastric carcinoma cell lines. Cancer Chemother Pharmacol 33: 43-7, 1993.
21. Gietema JA, de Vries EGE, Sleijfer DTh, Willemse PHB, Guchelaar H-J, Uges DRA, Aulenbacher P, Voegeli R and Mulder NHA: Phase I study of 1,2-diamminomethyl-cyclobutane-platinum(II)-lactate (D-19466; Lobaplatin) administered daily for 5 days. Brit J Cancer 67: 396-401, 1993.
22. Weiss RB and Christian MC: New cisplatin analogues in development A Rreview. Drugs 46(3): 360-77, 1993
23. Christian MC: The current status of new platinum analogs. Seminars Oncol 19: 720-33, 1992.
24. Gietema JA, Veldhuis GJ, Guchelaar H-J, Willemse PHB, Uges DRA, Cats A, Boonstra H van der Graaf WTA, Sleijfer DTh, de Vries EGE and Mulder NH: Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Brit J Cancer 71: 1302-7, 1995.
25. Kavanagh JJ, Edwards CL, Freedman RS, Finnegan RN, Alt O, Resukosol D, Urk K, Oechner S, Ord M, Ranklin JL and Udelka APA: Trial of lobaplatin (D-19466) in platinum resistant ovarian cancer. Gynecol Oncol 58: 106-9, 1995.
26. Degardin M, Armand JP, Chevallier B, Cappelaere P, Lentz M-A, David M and Roche HA: Clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Investigational New Drugs 13: 253-5, 1995.
27. Enneking WFA: System of staging musculoskeletal neoplasms. Clin Orthop 204: 9-24, 1986.
28. Hammer AS, Weeren FR, Weisbrode SE and Padgett SL: Prognostic factors in dogs with osteosarcomas of the flat or irregular bones. J Am Anim Hosp Assoc 31: 321-6, 1995.
29. Misdorp W and Hart AAM: Some prognostic and epidemiologic factors in canine osteosarcoma. J Nat Cancer Inst 62: 537-45, 1979.
30. Kirpensteijn J, Kik M, Rutteman GR and Teske E: Prognistic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol 39: 240-246, 2002.
31. Sternberg CN, de Mulder P, Fossa S, Kaye S, Roberts T, Pawinksy A, and Daamen S: Lobaplatin in advanced urothelial tract tumors. Ann Oncol 8: 695-6, 1997.
32. Meyer KB and Madias NE: Cisplatin nephrotoxicity. Mineral electrolyte metabolism 20: 201-13, 1994.
33. Bin P, Boddy AV, English MW, Pearson ADJ, Price L, Tilby MJ and Newell DR: The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in pediatric patients: A review. Anticancer Res 14: 2279-84, 1994.
34. Ehrhart N, Dernell WS, Hoffman WE, Weigel RM, Powers BE and Withrow SJ: Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996), J Am Vet Med Assoc 213(7): 1002-6, 1998.
35. Powers BE, Withrow SJ, Thrall DE, Straw RC, LaRue SM, Page RL and Gillete EL: Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 67: 126-34, 1991.
36. Yudoh K, Matsui H, Kamanori M, Ohmori K, Yasuda T, Tsuji H and Tatezaki S-I: Prognostic value of the doubling time of serum c-reactive protein and alkaline phosphatase levels in primary bone and soft tissue tumors. Jap J Cancer Res 87: 1288-95, 1996.
37. Harstrick A, Vanhoefer U, Heidemann A, Druyen H, Wilke H and Seeber S: Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin-a new clinically active platinum analog in established human cancer cell lines. Anti-Cancer Drugs 8: 391-5, 1997.